The microtubule-associated protein tau aggregates intracellularly by unknown mechanisms in Alzheimer's disease and other tauopathies. A contributing factor may be a failure to break down free cytosolic tau, thus creating a surplus for aggregation, although the proteases that degrade tau in brain remain unknown. To address this issue, we prepared cytosolic fractions from five normal human brains and from perfused rat brains and incubated them with or without protease inhibitors. D-Phenylalanyl-L-prolylarginyl chloromethyl ketone, a thrombin-specific inhibitor, prevented tau breakdown in these fractions, suggesting that thrombin is a brain protease that processes tau. We next exposed human recombinant tau to purified human thrombin and analyzed the fragments by N-terminal sequencing. We found that thrombin proteolyzed tau at multiple arginine and lysine sites. Furthermore, paired helical filament tau prepared from Alzheimer's disease brain was more resistant to thrombin proteolysis than following dephosphorylation by alkaline phosphatase. The results suggest a possible role for thrombin in proteolysis of tau under physiological and/or pathological conditions in human brains. They are consistent with the hypothesis that phosphorylation of tau inhibits proteolysis by thrombin or other endogenous proteases, leading to aggregation of tau into insoluble fibrils.Intracellular aggregates of the microtubule-associated protein tau are one of the pathological hallmarks of Alzheimer's disease. They are also the hallmark of a number of other neurodegenerative diseases that are now collectively referred to as tauopathies. Thus far, the biochemical features of aggregated tau have been most extensively studied in the paired helical filaments (PHFs) 1 of Alzheimer's disease brains. They include hyperphosphorylation (1), glycation (2, 3), glycosylation (4), ubiquitination (5), isomerization (6), and nitration (7). Of these, hyperphosphorylation is the most common feature of aggregated tau in tauopathies. The mechanism of tau aggregation still remains unknown, however. One hypothesis is that impaired proteolysis of tau perturbs tau turnover, leading to its availability for aggregation (8). In vitro, tau has been reported to be a substrate for a number of proteases such as trypsin, chymotrypsin, cathepsin D, calpains, caspases, proteasomal proteases, double-stranded DNA-stimulated protease, and thrombin (9 -15). However, the proteases that degrade tau or the factors that affect its function in brain are still unclear.To clarify these issues, we examined tau breakdown in cytosolic fractions extracted from five normal human brains incubated at 37°C with or without various kinds of protease inhibitors. Here, we show that a thrombin-specific inhibitor, D-phenylalanyl-L-prolylarginyl chloromethyl ketone (PPACK), completely repressed tau breakdown in this fraction. PPACK also inhibited tau breakdown in the same fraction prepared from perfused rat brains, indicating that thrombin in sufficient quantity for degrading tau is present in brain...